IL6 and congenital rubella syndrome: Current clinical protocols to treat CRS include glucocorticoids and/or IL-6 blockade (tocilizumab) (1, 52), whereas preemptive or early intervention with tocilizumab has been reported to prevent severe CRS (53, 54).